ALA·Arovella Therapeutics·CD19-positive non-Hodgkin lymphoma and leukaemia·Phase 1·NCT07518329·Primary completion: 31 Mar 2030
Plain-language Brief
The trial in plain terms
The disease
These are blood cancers where the cancerous cells are a type of white blood cell called a B cell. CD19 is a protein on the surface of those cells that drugs can be targeted at. The biggest disease in this group is diffuse large B-cell lymphoma, the most common aggressive lymphoma; chronic lymphocytic leukaemia and several rarer subtypes round out the picture. Several drugs that target CD19 are already approved (Yescarta, Kymriah, Breyanzi, Tecartus, plus the antibody-based products Columvi and Epkinly) and have transformed outcomes for some patients. The unmet need is in patients who relapse after those treatments, in patients who cannot wait the four to six weeks it takes to make a personalised cell therapy, and in markets where the current products are not commercially available.
What the asset is trying to do
ALA-101 is an off-the-shelf cell therapy: a frozen, ready-to-use product made in batches from healthy donor cells rather than custom-built for each patient. The cells used are a less common type of immune cell called invariant natural killer T cells (iNKT for short), engineered to recognise the CD19 protein on cancerous B cells. Arovella's argument for picking this cell type is safety: iNKT cells lack a feature of standard T cells that can cause donor cells to attack the recipient (a complication called graft-versus-host disease, or GvHD). If that argument holds in patients, ALA-101 could deliver donor-sourced cell therapy without the genetic editing other off-the-shelf products require to suppress GvHD risk.
What the trial is measuring, and why it matters
This is the first time ALA-101 will be given to patients. The trial is set up to answer three questions, in order: is the product safe to give, what is the highest dose patients can tolerate, and is there an early hint that it works. The main measurements are safety markers (immune over-reactions, brain side effects, infections, low blood cell counts), plus the identification of a dose level to carry forward into the next trial. Efficacy measures such as response rate are secondary at this stage and should be read as directional, not definitive: small dose-escalation cohorts cannot tell apart drugs with similar response rates.
Efficacy benchmarks in this setting
Trial Design
Design summary
Phase
Phase 1
Design type
Open-label, multi-centre, dose-escalation followed by dose-expansion. Single-arm.
Primary endpoint
Safety and tolerability (incidence and severity of adverse events, dose-limiting toxicities) and identification of a recommended Phase 2 dose.
Key secondary endpoints
Overall response rate (ORR)
Complete response rate (CR)
Duration of response
Cell persistence and pharmacokinetics
Progression-free and overall survival (descriptive at this stage)
Enrolment target
46 patients (per ClinicalTrials.gov NCT07518329)
Current enrolment status
Not yet recruiting (per ClinicalTrials.gov, as of latest sync). First patient dosing not yet announced.
Sites
Initial sites planned across Australia and New Zealand under the Clinical Trial Notification (CTN) scheme; US sites to open following IND clearance (IND filed September 2025). Named sites not yet disclosed.
Expected readout window
First-patient-dosed targeted for 2H 2026 (per Arovella IR). Initial safety / dose-finding read from low-dose cohorts plausibly late 2026 or 1H 2027; meaningful efficacy data unlikely before 2028 given typical dose-escalation cohort cadence and the 46-patient enrolment target.
Asset Track Record
Did ALA deliver against its own guidance?
Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
4 May 2026otherBoard Refresh and CEO Resignationhitsrc
Class Catalyst Calendar
What's landed, what's next for ALA-101 and peers
ALA-101's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for ALA-101. Showing past 6 months and next 12 months · 35 earlier hidden · 1 later hidden.
EPCORE NHL-1: epcoritamab (Epkinly) first-in-human trial in r/r B-cell lymphomapositivefollow up
Read-acrossThe EPCORE NHL-1 3-year follow-up demonstrates durable clinical benefit with epcoritamab in heavily pretreated r/r LBCL (39% prior CAR-T, 75% refractory to ≥2 lines). CR durability (median 36.1 months, longest >43 months) and OS benefit in complete responders (NR vs 18.5 months overall) support the value proposition of CD3xCD20 bispecific approaches as a mature alternative to autologous CAR-T in relapsed settings. This long-term dataset strengthens the competitive positioning of bispecific mechanisms within the ALA-101 asset class, particularly for patients unsuitable for or refractory to cellular therapies.
Trial design comparison
How ALA-101 reads against active peer trials
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
Trial
Sponsor
Class
Phase / Line
Design
Primary endpoint
Dosing
Key eligibility
n
ALA-101
Arovella Therapeutics
Allogeneic CD19 CAR-iNKT
Phase 1r/r
Open-label, multi-centre, dose-escalation followed by dose-expansion. Single-arm.
Safety and tolerability (incidence and severity of adverse events, dose-limiting toxicities) and identification of a recommended Phase 2 dose.
See trial design above
46 patients (per ClinicalTrials.gov NCT07518329)
46
Competitor Landscape
Competing programmes by mechanism and phase
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
No third-party coverage curated for ALA-101 yet. Broker coverage of Arovella Therapeutics is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.
The approved CD19 cell therapies set the published efficacy reference for this setting. In their pivotal trials, the autologous CAR-T products report complete-response rates of roughly 40 to 60 percent in heavily pre-treated large B-cell lymphoma (Yescarta and Breyanzi US prescribing information; ZUMA-1 long-term follow-up, Locke et al). ALA-101 is a first-in-human Phase 1 whose primary measures are safety and dose-finding; efficacy figures from small dose-escalation cohorts are not statistically comparable to these benchmarks, which are shown here for context only.
Commercial context
Several CD19-targeted therapies are already approved for B-cell lymphoma and leukaemia: the autologous CAR-T products Yescarta, Kymriah, Breyanzi and Tecartus, and the bispecific antibodies Columvi and Epkinly (FDA labels). No off-the-shelf (allogeneic) CD19 cell therapy is currently approved. ALA-101 is Arovella's lead clinical asset and remains in Phase 1; manufacturing cost and pricing details for the product have not been disclosed.
Read-acrossStrongest off-the-shelf CD19 CAR-T data to date — response and durability "on par with autologous" in 2L LBCL per sponsor framing. Sets a higher bar than ALPHA2 for what allogeneic CAR-T can achieve, and tightens the safety case ALA-101 must meet to differentiate iNKT vs gene-edited T.
Read-acrossCTX110 demonstrates clinically meaningful efficacy in heavily pretreated r/r NHL (65% ORR, 39% CR) with a manageable toxicity profile and evidence that dual infusions extend response duration. For ALA-101 investors, this represents a positive competitive readout for allogeneic CD19 CAR-T in the r/r setting, establishing CTX110 as a clinically active comparator though durable CR rates (23% ongoing) remain modest and require longer follow-up data.
May 2026
ALPHA3: cemacabtagene ansegedleucel (cema-cel) as 1L MRD+ consolidation in LBCLcautiousinterim
Read-acrossThe interim futility analysis from ALPHA3 demonstrates 58.3% MRD negativity in the cema-cel consolidation arm, supporting continuation of the Phase 3 pivotal programme. For ALA-101 investors, this data validates allogeneic CAR-T as a viable 1L consolidation modality in MRD-positive LBCL, positioning cema-cel as a potential standard-of-care alternative to autologous approaches if efficacy is sustained at primary completion.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
ALPHA3: cemacabtagene ansegedleucel (cema-cel) as 1L MRD+ consolidation in LBCL
Donor-sourced T cells engineered to express a CD19 CAR, manufactured in batches and stored frozen. Aims to remove the per-patient manufacturing wait and lower cost-of-goods, at the cost of needing genetic edits to prevent host rejection and graft-versus-host disease.
Class benchmarks
No approved product despite multiple clinical-stage entrants since 2018 (Allogene, Caribou, Cellectis, Precision, Atara historically). Reported response rates have been competitive on first infusion but durability has lagged autologous CAR-T, with most trials showing rapid loss of cells and shorter median duration of response.
Commercial track record
Class economics depend entirely on durability. If durable remissions are achievable, the off-the-shelf logistics and lower cost should win significant share from autologous CAR-T. If durability remains weak, the class is squeezed between autologous (efficacy) and bispecifics (logistics) with no clear position.
Capital intensity
Lower cost-of-goods than autologous in principle (batch manufacturing, no apheresis), but actual margins depend on dose size, redosing requirements, and lymphodepletion intensification. No public proof point yet.
Regulatory posture
No precedent for an approved allogeneic CD19 CAR-T. Pivotal trial designs have been disputed; Allogene paused ALPHA2 in 2021 over a chromosomal abnormality scare that resolved without consequence but cost the field 12 months. Watch ALPHA3 (1L MRD+ consolidation) as the most pivotal-intent design in the class.
Donor-sourced natural killer cells (often from cord blood) engineered to express a CD19 CAR. NK cells do not require lymphodepletion in the same way and have a fundamentally different safety profile: lower CRS, no GvHD, but historically shorter persistence in vivo.
Class benchmarks
No approved product. Most-watched programme is Takeda/MD Anderson TAK-007 (cord-blood derived). Early single-centre data showed encouraging response rates in r/r B-cell lymphoma; the larger Takeda-sponsored Phase 2 will be the readout that establishes the class.
Commercial track record
Stronger safety thesis than allogeneic CAR-T (no GvHD risk, lower CRS) but unproven durability. If safety advantage holds in larger trials, NK approach may find a niche in earlier lines or in autoimmune indications (Nkarta is dual-tracking).
Capital intensity
Cord-blood sourced products face supply-chain constraints; iPSC-derived NK programmes (Fate Therapeutics historically) have aimed at scale but have not delivered an approval. Per-dose economics not yet established.
4 approved · 0 active · 2 historicalexpand ›collapse ‹
Class profileexpand ›collapse ‹
Description
Patient-derived T cells engineered to express a CD19 CAR. The class that established CAR-T as a cancer modality. Manufacturing is per-patient and slow (typically four to six weeks), and product cost is high.
Class benchmarks
Four approved products (Yescarta, Kymriah, Breyanzi, Tecartus). Reported complete response rates in pivotal trials run from roughly 40 to 60 percent in heavily pretreated large B-cell lymphoma. Durable remissions extend beyond five years in a meaningful subset.
Commercial track record
Yescarta peak sales above $1.5B annualised. Total class revenue is multi-billion. Commercial barriers are real (REMS, certified treatment centres, manufacturing capacity), creating moat for incumbents but limiting access. Off-the-shelf entrants compete on speed and price, not on raw efficacy.
Capital intensity
Highest of any oncology modality. Each treatment requires apheresis, freight, GMP cell manufacture, and certified administration. Cost-of-goods commonly cited above $100K per dose. Margin pressure is the main commercial vulnerability.
2 approved · 1 active · 1 historicalexpand ›collapse ‹
Class profileexpand ›collapse ‹
Description
CD20xCD3 T-cell engagers. Same mechanistic logic as CD19xCD3 with CD20 as the tumour-side target. Currently the more clinically validated of the two B-cell bispecific subclasses.
Class benchmarks
Approved products: epcoritamab (Epkinly, Genmab/AbbVie), glofitamab (Columvi, Roche), mosunetuzumab (Lunsumio, Roche). Pivotal CR rates in r/r LBCL roughly 35-50%. Durability shorter than CAR-T but with a meaningful tail.
Commercial track record
Direct off-the-shelf competition for cellular CD19 in r/r B-cell NHL. Lower cost, simpler administration, broader prescribing footprint. Genmab and Roche are the leading commercial players.
Capital intensity
Standard biologic. Sub-$10K cost-per-cycle range commonly cited; total course cost depends on duration of dosing.
Regulatory posture
68 sites·6 top centres: MD Anderson, City of Hope, +4
PIs: Matthew Ulrickson, Stephen Divers, Oleg Krijanovski, +63KOL note
Readout · 13 May 2026interim· interim analysiscautiousAI-extracted
Read-acrossThe interim futility analysis from ALPHA3 demonstrates 58.3% MRD negativity in the cema-cel consolidation arm, supporting continuation of the Phase 3 pivotal programme. For ALA-101 investors, this data validates allogeneic CAR-T as a viable 1L consolidation modality in MRD-positive LBCL, positioning cema-cel as a potential standard-of-care alternative to autologous approaches if efficacy is sustained at primary completion.
Read-acrossPivotal-intent trial in 1L consolidation. Validates an off-the-shelf CD19 cellular product in a much larger commercial setting than r/r; if successful, reframes the entire allogeneic-CD19 opportunity.
Stopped — business / portfolio
CARBON: CTX110 (allogeneic CD19 CAR-T, gene-edited) in r/r B-cell malignancies
Readout · 5 May 2026· primary completionpositiveAI-extracted
Read-acrossCTX110 demonstrates clinically meaningful efficacy in heavily pretreated r/r NHL (65% ORR, 39% CR) with a manageable toxicity profile and evidence that dual infusions extend response duration. For ALA-101 investors, this represents a positive competitive readout for allogeneic CD19 CAR-T in the r/r setting, establishing CTX110 as a clinically active comparator though durable CR rates (23% ongoing) remain modest and require longer follow-up data.
Read-acrossCRISPR pivoted CD19 cell therapy out of oncology to autoimmune in late 2023. Durability data was viewed as insufficient versus autologous benchmarks but the formal stop was strategic. Read-across for ALA-101: one fewer allogeneic CD19 CAR-T competitor in oncology; not a class-wide safety or efficacy invalidation.
ALPHA2: cemacabtagene ansegedleucel (cema-cel) in r/r LBCL
Threatr/rPhase 1/2
r/r LBCL, CLL/SLL
Allogene Therapeutics($300M mcap, $455M cash)·Active, not recruiting·last update 1y ago·Primary completion 31 Dec 2026·NCT04416984
OrphanFast Track
29 sites·6 top centres: MD Anderson, Mayo Clinic, +4
Readout · 10 May 2025· follow uppositiveAI-extracted
Read-acrossCemacabtagene ansegedleucel demonstrates durable efficacy in r/r LBCL with manageable toxicity and no GVHD—a key advantage over autologous CAR-T. The 23.1-month median DoR in CR patients and absence of severe CRS/ICANs strengthen the safety/tolerability profile for allogeneic CAR-T as a potential off-the-shelf therapy. This supports ongoing Phase III evaluation (ALPHA3) and positions ALA-101 as a leading allogeneic CD19 CAR-T candidate in the competitive r/r LBCL landscape.
Read-acrossPhase 1 data for the allogeneic CD19 CAR-T modality shows responses can be durable when a CR is achieved (median DOR 23.1mo). ALA-101 does not need to match these numbers as an iNKT product, but a flat response rate well below 40% in dose-escalation would call the off-the-shelf cell-therapy thesis into question.
Read-acrossThe clinical event that defines the off-the-shelf-cell-therapy safety conversation. FDA placed Allogene's entire AlloCAR T program on hold after a chromosomal abnormality was detected in an ALPHA2 patient. Investigation concluded the abnormality was unrelated to TALEN gene editing or manufacturing and occurred post-infusion (lifted Jan 2022). The hold did not falsify the modality, but it raised the diligence bar for any allogeneic CAR-T program and is the safety incident that motivates platforms like ALA-101's iNKT scaffold — which avoids gene editing entirely.
Read-acrossMost-watched allogeneic CD19 CAR-T readout. Positive durability would set the benchmark ALA-101 must approach; safety signals (especially GvHD or prolonged cytopenias) would expand the case for an iNKT-based approach.
~15mo runway
ANTLER: vispa-cel (CB-010, allogeneic CD19 CAR-T) in r/r B-NHL
38 sites·3 top centres: MD Anderson, Penn / Abramson, +1
Readout · 5 Feb 2026· primary endpointpositive
ORR82%(n=22)
CR64%(n=22)
12-month PFS51%(n=22)
Read-acrossStrongest off-the-shelf CD19 CAR-T data to date — response and durability "on par with autologous" in 2L LBCL per sponsor framing. Sets a higher bar than ALPHA2 for what allogeneic CAR-T can achieve, and tightens the safety case ALA-101 must meet to differentiate iNKT vs gene-edited T.
Read-acrossPD-1 knockout CD19 CAR-T using CRISPR. Direct allogeneic peer; durability data is the key swing factor for the entire class.
Regulatory posture
No CD19 CAR-NK approved. FDA has been receptive to safety-led arguments but will require durability data. Class is likely to need different label positioning than CAR-T.
15 sites·2 top centres: Columbia / NYP, MD Anderson
27/70 enrolled
Readout · 6 Feb 2020interim· primary endpointpositive
Objective response rate73%(n=11)
Complete response rate64%(n=11)
Grade 3+ cytokine release syndrome0%(n=11)
Read-acrossStrongest public proof point that an off-the-shelf CD19 effector cell can deliver autologous-comparable response rates with a cleaner safety profile. Direct read-across for ALA-101 if the iNKT scaffold preserves the same safety advantages.
Read-acrossMost advanced CAR-NK in CD19. Shares the off-the-shelf safety profile thesis with iNKT; a clean readout strengthens the case that non-T allogeneic effectors can match autologous CAR-T efficacy.
Takeda discontinued B-cell development May 2024 in R&D rethink; autoimmune development continues separately. Final B-NHL data: ORR 53.8%, CR 30.8% (n=26) presented at ASH 2024.
NKX019: allogeneic CD19 CAR-NK in B-cell malignancies and lupus
Tailwindr/rPhase 1
r/r B-cell malignancies + lupus
Nkarta($100M mcap, $267M cash)·Active, not recruiting·last update 1y ago·Primary completion 31 Dec 2026·NCT05020678
Orphan
6 sites·1 top centre: Peter MacCallum
PI: David Shook
Dual-track development (oncology + autoimmune) signals confidence in the safety profile. iNKT shares many of the same persistence and safety arguments.
Regulatory posture
Accelerated approval pathway is well-trodden in this class. REMS programmes mandatory due to CRS and neurotoxicity risk. Label expansion into earlier lines of therapy is the current commercial battleground.
36 sites·7 top centres: MD Anderson, City of Hope, +5
307/111 enrolled
Readout · 1 May 2025· post hocpositiveAI-extracted
Read-acrossThis post-hoc MAIC analysis demonstrates that axicabtagene ciloleucel (Yescarta) maintains strong comparative efficacy versus historical standard of care in Asian descent patients with r/r LBCL, with a 73% reduction in mortality risk (HR 0.27) and substantial improvements in response rates. The consistency of efficacy between Western (original ZUMA-1) and Asian populations strengthens the global clinical case for the curated asset's CAR-T pipeline and supports reimbursement arguments in Asia-Pacific markets, a key growth region for cell therapies.
Read-acrossSets the efficacy bar (~40% durable CR at 5yr in r/r LBCL). ALA-101 does not need to match autologous on response rate to win; access, manufacturing turnaround, and bridging-free use are the differentiators investors will price.
Pivotal trial · drug approved
TRANSCEND NHL 001: lisocabtagene maraleucel (Breyanzi) in r/r B-NHL
Roche($220B mcap)·Completed·last update 1y ago·Primary completion 31 Dec 2024·NCT03075696
OrphanAccelerated Approval
34 sites·3 top centres: Memorial Sloan Kettering, Peter MacCallum, +1
Readout · 20 Jan 2025· primary completionpositiveAI-extracted
Read-acrossGlofitamab achieved robust CR (78.3%) and ORR (85.0%) in heavily pretreated R/R MCL, a notoriously difficult-to-treat population. While CRS remained common (70% incidence), the higher-dose obinutuzumab pretreatment regimen substantially mitigated grade ≥2 CRS (22.7% vs 62.5%), demonstrating a favorable safety/efficacy profile. This reinforces bispecific CD20–CD3 antagonism as an effective mechanism in CD19+ lymphomas and supports the competitive positioning of CD19 CAR therapies (ALA-101 curated asset) versus next-gen bispecifics in the r/r B-NHL landscape.
Read-acrossAlready approved with fixed-duration dosing. The cleanest argument for cellular therapy over bispecifics is durability of single-course response; that data needs to come from the Phase 1 readout.
EPCORE NHL-1: epcoritamab (Epkinly) first-in-human trial in r/r B-cell lymphoma
Threatr/rPhase 1/2
r/r LBCL
Genmab / AbbVie($15B mcap)·Active, not recruiting·last update 9mo ago·Primary completion 30 June 2026·NCT03625037
OrphanAccelerated Approval
85 sites·4 top centres: Mayo Clinic, MD Anderson, +2
Read-across
AI-extracted
Read-acrossThis post-hoc analysis of ZUMA-1 reveals significant disparities in axi-cel efficacy across racial/ethnic groups: NH Black patients showed materially lower ORR, CRR, and PFS vs NH White and Asian patients, raising important clinical and equity considerations for CAR-T deployment. While safety profiles were broadly consistent, these outcome differences may influence patient selection, real-world uptake patterns, and future trial design for CD19 CAR-T therapies competing in this space, including allogeneic alternatives that might mitigate patient-specific biology.
Read-acrossZUMA-1 Cohort 5 exploratory analysis demonstrates that pre-treatment debulking with chemotherapy or radiotherapy is feasible in heavily pretreated R/R LBCL patients (40% with ≥3 prior lines) and achieves comparable ORR/CRR (72%/56%) to the pivotal cohorts, but with higher serious treatment-emergent adverse-event burden. While debulking may modestly reduce CRS/neurologic event severity, the incidence of grade ≥3 cytopenias (36–48%) was substantial, suggesting the risk/benefit profile did not materially improve. This informs real-world implementation of axi-cel and supports the importance of pre-treatment cytopenias assessment and management in this patient population.
Readout · 11 May 2023· follow uppositiveAI-extracted
Read-acrossZUMA-1's 5-year durability data strengthens the evidence for CD19 CAR-T efficacy in r/r LBCL, with 42.6% long-term OS and sustained responses without protracted B-cell aplasia. This establishes a clinical benchmark for the curated asset (ALA-101) competitor portfolio: allogeneic CAR-T and CAR-NK programmes must demonstrate equivalent or superior long-term survival and safety profiles to justify advancement in this heavily validated indication.
Read-acrossSets the durability bar for any CD19-directed therapy. ALA-101 does not need to match the 58% CR but Phase 1 results well below this range would call the platform thesis into question.
Readout · 1 Nov 2021interim· safety updatepositiveAI-extracted
Read-acrossCohort 4 of ZUMA-1 demonstrates that earlier, measured corticosteroid/tocilizumab dosing reduces severe CRS and neurologic toxicity (grade ≥3 rates of 2% and 17% respectively, with zero grade 4–5 events) while maintaining robust efficacy (73% ORR, 51% CRR). This toxicity-mitigation strategy strengthens the safety profile of axi-cel and supports broader adoption; for investors tracking CD19 CAR-T competitive landscapes, this refined management approach positions Yescarta favourably against newer allogeneic platforms.
Readout · 26 Oct 2021· follow uppositiveAI-extracted
Read-acrossZUMA-1's 2-year durability data (54% OS, 83% ORR) in refractory LBCL demonstrates substantial survival advantage over conventional salvage chemotherapy, reinforcing the competitive position of CD19 CAR-T autologous therapies in the r/r LBCL space. This long-term efficacy benchmark sets a high bar for allogeneic CD19 CAR-T and bispecific competitors in the ALA-101 pipeline, particularly for agents claiming durability or tolerability advantages.
Readout · 1 Oct 2021· follow upcautiousAI-extracted
Read-acrossThis 24-month follow-up analysis from ZUMA-1 demonstrates that axicabtagene ciloleucel induces sustained CD19 CAR-T responses but carries significant late immunotoxicity risks: delayed CD4+ T-cell recovery (29-33% with counts <200/mL at 1-2 years), persistent hypogammaglobulinemia (44% without normalization by year 2), and opportunistic infections in 42% of patients. For investors evaluating ALA-101 (a competing CD19 CAR-T program), these durability and safety data highlight the benchmark for long-term tolerability and the commercial need for better infection prophylaxis protocols and immune reconstitution strategies in autologous CD19 CAR-T therapies.
Readout · 1 Aug 2021interim· safety updatepositiveAI-extracted
Read-acrossThis ZUMA-1 cohort 6 readout demonstrates that prophylactic dexamethasone with early tocilizumab intervention substantially mitigates CAR-T toxicity: zero grade ≥3 CRS and only 13% grade ≥3 neurologic events while maintaining high response rates (95% ORR, 80% CRR). For ALA-101 as a CD19 CAR-T asset, this establishes a validated safety-management framework that could inform clinical-trial design and labelling, potentially reducing the toxicity burden that has historically limited autologous CAR-T adoption.
Readout · 13 Oct 2020· post hocpositiveAI-extracted
Read-acrossThis post-hoc biomarker analysis from ZUMA-1 identifies key biological drivers of durable response to autologous CD19 CAR-T therapy—specifically T-cell fitness, expansion kinetics, and host inflammation status—rather than standard prognostic factors. These mechanistic insights strengthen the clinical rationale for CD19 CAR-T approaches in r/r LBCL and suggest optimization paths (product manufacturing, patient selection, inflammation management) that could inform competitor trials (allogeneic CAR-T, bispecifics) in the same indication.
Readout · 1 Oct 2020· primary completionpositiveAI-extracted
Read-acrossZUMA-1 demonstrated that autologous CD19 CAR-T (axicabtagene ciloleucel) achieves 66% ORR and 47% CR in r/r LBCL with manageable toxicity, supporting EMA approval and establishing a clinical benchmark. For the curated asset ALA-101, this positive readout reinforces the competitive landscape: allogeneic CD19 CAR-T and CAR-NK programmes (ALPHA2, ALPHA3, CARBON, ANTLER, TAK-007, NKX019) must demonstrate similar or superior efficacy with lower manufacturing burden and off-the-shelf accessibility to justify their development relative to the now-approved autologous standard.
Readout · 1 Jan 2019· follow uppositiveAI-extracted
Read-acrossZUMA-1 2-year follow-up data confirms axicabtagene ciloleucel (Yescarta) maintains durable responses in r/r LBCL with 83% ORR and median OS not yet reached at 27 months, establishing a strong clinical precedent for CD19 CAR-T efficacy and durability. The manageable long-term safety profile (no new treatment-related deaths post-year 1, stable neurotoxicity at 32%) supports viability of this mechanism in ALA-101's competitive landscape. This mature data reinforces CD19 CAR-T as a standard-of-care benchmark against which newer allogeneic and bispecific competitors (NKX019, TAK-007, epcoritamab, glofitamab) will be evaluated.
Readout · 28 Dec 2017· primary completionpositiveAI-extracted
Read-acrossZUMA-1 phase 2 data demonstrates that autologous CD19 CAR-T (axi-cel) achieves robust durable responses (82% ORR, 54% CR) in heavily pre-treated r/r LBCL, with acceptable but notable toxicity (13% CRS, 28% neurotox grade 3+). This establishes a meaningful efficacy and safety benchmark for the CD19 CAR-T cell therapeutic class, informing how ALA-101 and competing allogeneic CAR-T/CAR-NK approaches must perform to differentiate clinically or reduce toxicity burden.
Read-acrossLiso-cel (Breyanzi) achieves a 83% ORR and 72% CR in heavily pretreated R/R MCL patients, including those with BTKi-refractory and high-risk disease, with a manageable safety profile (grade 3/4 CRS only 1%, no grade 5 CRS). This MCL cohort primary analysis from TRANSCEND NHL 001 strengthens the clinical profile of autologous CD19 CAR-T as a durable option in difficult-to-treat B-cell lymphomas, relevant to competitive positioning of allogeneic CAR-T and CAR-NK assets in the r/r lymphoma space.
Readout · 1 Feb 2024· follow uppositiveAI-extracted
Read-acrossTRANSCEND NHL 001's two-year follow-up demonstrates durable remissions (53% CR, 73% ORR) with manageable toxicity in heavily pre-treated r/r LBCL patients. The 50.5% two-year OS rate and median OS of 27.3 months, combined with low rates of severe CRS (2%) and neurological events (10%), support the clinical profile of autologous CD19 CAR-T. This long-term durability data strengthens the position of CD19-directed approaches as a competitive benchmark in the r/r LBCL space, relevant for positioning of allogeneic CAR-T and bispecific alternatives in the ALA-101 investment thesis.
Readout · 1 Mar 2023· post hocpositiveAI-extracted
Read-acrossThis post-hoc synthetic-control analysis of TRANSCEND NHL 001 demonstrates statistically significant and clinically substantial superiority of liso-cel over conventional therapy across all major efficacy endpoints in third-line or later r/r LBCL. For ALA-101 investors, this reinforces liso-cel's established position as a transformative therapy in heavily pretreated LBCL and provides additional real-world comparative evidence supporting its clinical value proposition relative to older standard-of-care approaches.
Readout · 1 July 2022· post hocpositiveAI-extracted
Read-acrossThis post-hoc pharmacokinetic analysis of TRANSCEND NHL 001 provides mechanistic support for liso-cel efficacy and reveals predictive biomarkers (in vivo expansion) for response and toxicity in r/r LBCL. The findings strengthen the clinical rationale for liso-cel as a CD19 CAR-T benchmark and inform patient selection/monitoring strategies. However, the association of higher expansion with increased neurological events and CRS highlights a safety-efficacy tradeoff that competitors (particularly allogeneic CAR-T and bispecific platforms) may attempt to address through improved tolerability profiles.
Read-acrossThis secondary HRQoL analysis from TRANSCEND NHL 001 demonstrates that lisocabtagene maraleucel (Breyanzi), a CD19 CAR-T therapy, delivers sustained, clinically meaningful improvements in patient quality of life and fatigue in r/r LBCL, with benefits correlating to antitumor responders. For ALA-101 investors, this underscores the clinical value-add of CAR-T approaches beyond efficacy—important for reimbursement and market differentiation in the competitive r/r B-NHL space.
Readout · 23 Mar 2021interim· safety updatecautiousAI-extracted
Read-acrossTRANSCEND NHL 001 demonstrates that lisocabtagene maraleucel (Breyanzi) achieves manageable safety with ~77% of CRS/neurological events being grade ≤2 in a 268-patient cohort. However, 23% of patients experienced grade ≥3 toxicities with substantial cost burden (~$177k for concurrent severe events). For investors assessing the competitive landscape of CD19 CAR-T therapies, this safety readout supports Breyanzi's clinical profile but highlights that severe AE management remains a material cost driver in CAR-T treatment, raising the bar for next-generation allogeneic platforms on the ALA-101 competitive set.
Read-acrossTRANSCEND NHL 001 demonstrates that lisocabtagene maraleucel (Breyanzi) achieves a robust 73% objective response rate with 53% complete response in heavily pre-treated r/r LBCL patients (97% with ≥2 prior lines, 67% chemotherapy-refractory). The safety profile is favourable relative to other CD19 CAR-T therapies, with grade 3+ cytokine release syndrome in only 2% and grade 3+ neurological events in 10%, supporting the clinical utility of this allogeneic platform and providing a strong efficacy/safety comparator for ALA-101's development in r/r B-cell malignancies.
Read-acrossCleanest neurotoxicity profile of the autologous CD19 CAR-T class. ALA-101 safety data should be benchmarked against TRANSCEND, not the older ZUMA-1 numbers, since lisocabtagene set the modern bar.
Read-acrossAutologous benchmark with the cleanest neurotoxicity profile. ALA-101 safety claims should be framed against this, not against the older Yescarta data.
AI-extracted
Read-acrossGlofitamab demonstrates meaningful efficacy in heavily pre-treated r/r DLBCL (39% CR, 37% 12-month PFS) and notably remains effective in CAR-T-experienced patients (35% CR). Safety is manageable with pretreatment obinutuzumab, though 62% experienced grade ≥3 AEs. This establishes bispecific CD20-CD3 redirecting antibodies as a viable alternative to autologous CAR-T in the r/r LBCL space, providing important competitive context for allogeneic CAR-T programmes like ALA-101 pursuing similar indications.
Readout · 8 Feb 2022interim· post hocpositiveAI-extracted
Read-acrossGlofitamab demonstrates clear pharmacodynamic engagement and T-cell activation in r/r B-NHL, supporting its mechanism as a CD20×CD3 bispecific. The identification of TP53 signaling as a resistance biomarker provides valuable patient-selection insights for future development. This mechanistic validation strengthens the clinical rationale for bispecific antibodies in the CD19+ B-cell malignancy space, positioning glofitamab competitively within the ALA-101 asset class alongside CAR-T therapies.
Readout · 20 June 2021· primary completionpositiveAI-extracted
Read-acrossGlofitamab demonstrated favorable efficacy (57% CR at RP2D with 84% durability) and a manageable safety profile in heavily pretreated r/r B-NHL, establishing the bispecific CD20-CD3 mechanism as a validated approach. For ALA-101 investors, this validates the competitive landscape where CD3-engaging bispecific antibodies represent a proven alternative to CAR-T therapies, suggesting multiple pathways to CD19/CD20-targeted B-cell malignancy treatment and potential for differentiation on safety, durability, and manufacturing ease.
Readout · 4 Feb 2026· follow uppositiveAI-extracted
Read-acrossThe EPCORE NHL-1 3-year follow-up demonstrates durable clinical benefit with epcoritamab in heavily pretreated r/r LBCL (39% prior CAR-T, 75% refractory to ≥2 lines). CR durability (median 36.1 months, longest >43 months) and OS benefit in complete responders (NR vs 18.5 months overall) support the value proposition of CD3xCD20 bispecific approaches as a mature alternative to autologous CAR-T in relapsed settings. This long-term dataset strengthens the competitive positioning of bispecific mechanisms within the ALA-101 asset class, particularly for patients unsuitable for or refractory to cellular therapies.
Read-acrossCD20xCD3 bispecific durability now mature: median DOR of 36mo in complete responders is the off-the-shelf bar ALA-101 has to clear commercially, not just clinically. Epkinly is already approved and physician-familiar — the question for any new CD19 off-the-shelf entrant is what it adds vs an established, simple-to-administer antibody.
Readout · 1 Dec 2024· follow uppositiveAI-extracted
Read-acrossEpcoritamab demonstrates durable clinical benefit in r/r LBCL with 63% ORR and meaningful 24-month OS of 44.6%, including activity in hard-to-treat populations (CAR-T pre-treated, primary refractory, high IPI). This 2-year follow-up strengthens the competitive positioning of CD20×CD3 bispecific antibodies in the r/r LBCL landscape relative to CAR-T and other modalities tracked by ALA-101, supporting regulatory approval and market penetration.
Readout · 1 Aug 2024· primary completionpositiveAI-extracted
Read-acrossEpcoritamab demonstrates clinically meaningful efficacy (82% ORR, 62.5% CR) in multiply relapsed/refractory follicular lymphoma with a manageable safety profile, particularly after cycle 1 optimisation protocol reduced CRS from 65% (grade 1–2) to 49% and eliminated grade 3+ CRS. This positive phase 2 readout in follicular lymphoma strengthens the bispecific CD20×CD3 platform's competitive positioning; however, as a competitor asset to ALA-101 (a CD19-targeted CAR-T/NK platform), epcoritamab's different mechanism (CD20 rather than CD19) and non-CAR format represent an adjacent rather than directly comparable approach to relapsed/refractory B-cell lymphoma.
Readout · 1 Mar 2024· follow uppositiveAI-extracted
Read-acrossEpcoritamab demonstrates clinically meaningful improvements in patient-reported quality of life and symptom burden in heavily pretreated r/r LBCL patients, with FACT-Lym and EQ-5D improvements exceeding published minimally important difference thresholds and high patient satisfaction (80%). This PRO data strengthens the clinical value proposition of CD20×CD3 bispecific therapy (epcoritamab, Epkinly) as a competitor to autologous/allogeneic CAR-T platforms (Yescarta, Breyanzi) and other bispecific agents in the r/r LBCL landscape, supporting potential label expansion and market differentiation for ALA-101 in evaluating CD20×CD3 mechanism efficacy.
Read-acrossEpcoritamab (bispecific CD20×CD3) achieved an ORR of 63.1% and CRR of 38.9% in 157 heavily pre-treated r/r LBCL patients (median 3 prior lines, 61% primary refractory, 39% CAR-T exposed) with a median response duration of 12 months. This demonstrates that non-autologous CD20×CD3 bispecific approaches can achieve competitive efficacy to CAR-T in the r/r LBCL space with a subcutaneous, off-the-shelf delivery format; the manageable CRS profile and subcutaneous administration may offer practical advantages over CAR-T therapies, providing important context for evaluating allogeneic CAR-T platforms like ALA-101 as next-generation alternatives.
Read-acrossEpcoritamab dose-escalation data demonstrate a favourable safety and efficacy profile in r/r B-cell NHL, with no MTD reached, manageable CRS (all grade 1–2), and robust ORRs (88% at RP2D in DLBCL, 90% in FL). These encouraging phase 1/2 results support advancement to phase 2/3 and position epcoritamab as a competitive bispecific CD20-CD3 therapy within the broader ALA-101 CAR-T/allogeneic immunotherapy competitive set, though the autologous and allogeneic CAR-T programmes remain key comparators for relapsed/refractory disease.
Read-acrossOff-the-shelf bispecifics are the real commercial competitor for allogeneic CAR cellular: similar logistics, no apheresis. Investors will pressure-test why a cell therapy would win share against an antibody product.